Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
Pharma & Biotech
Pharma & Biotech
Savara selects PANTHERx as exclusive pharmacy for MOLBREEVI amid PAP BLA review
Savara names PANTHERx as exclusive pharmacy for MOLBREEVI in autoimmune PAP. Find out what this launch model means for access, adoption, and strategy.